<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636788</url>
  </required_header>
  <id_info>
    <org_study_id>E-sR2020</org_study_id>
    <nct_id>NCT04636788</nct_id>
  </id_info>
  <brief_title>Circulating Extracellular Exosomal Small RNA as Potential Biomarker for Human Pancreatic Cancer</brief_title>
  <official_title>Diagnostic and Prognostic Values of EUS-FNA Specimens and Circulating Exosomal Small RNA in Patients With Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for the verification of biomarkers for pancreatic cancer treatment using small&#xD;
      RNA liquid biopsy, combined with EUS-FNA tissues.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CA19-9 is the FDA approved biomarker for the diagnosis of pancreatic cancer. However, the&#xD;
      specificity of CA19-9 to differentiate between pancreatic cancer, cholangiocarcinoma, or&#xD;
      other pancreatic lesions is not satisfying enough.&#xD;
&#xD;
      Tumor cells secret abundant exosomes in the early stage. Circulating tumor cells are detected&#xD;
      mainly in the advanced stage. Meanwhile, the role of non-coding RNA draws more and more&#xD;
      attention in tumor area. Exosomes protect inside RNA from plasma RNase. Compared with long&#xD;
      RNA, small RNA, including miRNA, snoRNA, tRNA, piRNA could exist more stably.&#xD;
&#xD;
      By means of next-generation sequencing, we look forward to finding new exosomal small RNA&#xD;
      biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>senstivity</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>sensitivity of exo-sRNA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>specificity</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>specificity of exo-sRNA to differentiate between PAAD and other benigh or malignant pancreatic occupying lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival time</measure>
    <time_frame>up to 18 months</time_frame>
    <description>relationship between expression level of chosen exosomal RNA and patients' survival time in PAAD group</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Pancreas Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>pancreatic cancer group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>pancreatic cancer, anticipated participants: 68&#xD;
other pancreatic lesions including MCN, SCN, IPMN, SPN without malignant pathological finding chronic pancreatitis cholangiocarcinoma healthy control anticipated participants: 34</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Venous sampling</intervention_name>
    <description>venous sampling of 12ml</description>
    <arm_group_label>pancreatic cancer group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt;18&#xD;
&#xD;
          -  pancreatic cancer patients&#xD;
&#xD;
          -  pancreatic lesions other than PAAD&#xD;
&#xD;
          -  chronic pancreatitis&#xD;
&#xD;
          -  cholangiocarcinoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diagnosed with other pathological types of cancer&#xD;
&#xD;
          -  treated with chemo/radio/surgery previously&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bin Cheng, Professor</last_name>
    <phone>13986097542</phone>
    <email>b.cheng@tjh.tjmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College, HUST</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Cheng, Professor</last_name>
      <phone>13986097542</phone>
      <email>b.cheng@tjh.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Yuchong Zhao, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bin Cheng, M.D./Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 14, 2020</last_update_submitted>
  <last_update_submitted_qc>November 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Bin Cheng</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>exosome</keyword>
  <keyword>snoRNA</keyword>
  <keyword>endoscopic ultrasound</keyword>
  <keyword>liquid biopsy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

